相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Experimental design and modelling approach to evaluate efficacy of beta-lactam/beta-lactamase inhibitor combinations
S. K. B. Sy et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms
S. K. B. Sy et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model
Luning Zhuang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae
James Albiero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms
Sherwin K. B. Sy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model
Ami F. Mohamed et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model
Luning Zhuang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants
David D. Khan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48
Sushmita D. Lahiri et al.
ACS CHEMICAL BIOLOGY (2015)
In Vitro Activity of Ceftazidime-Avibactam Combination in In Vitro Checkerboard Assays
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model
Seth T. Housman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance
S. D. Lahiri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
Tiffany R. Keepers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
David E. Ehmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Elisabet I. Nielsen et al.
PHARMACOLOGICAL REVIEWS (2013)
Pharmacokinetic-Pharmacodynamic Model for Gentamicin and Its Adaptive Resistance with Predictions of Dosing Schedules in Newborn Infants
Ami F. Mohamed et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
Jared L. Crandon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
Premavathy Levasseur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Ceftazidime for respiratory infections
Sang-Ho Choi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)
A. Walkty et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Ken Coleman
CURRENT OPINION IN MICROBIOLOGY (2011)
Concentration-dependency of β-lactam-induced filament formation in Gram-negative bacteria
J. Buijs et al.
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo
Johan W. Mouton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Continuous administration of PBP-2- and PBP-3-specific β-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis
Jacqueline Buijs et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments
Elisabet I. Nielsen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics - The minimum inhibitory concentration versus stationary concentration
JW Mouton et al.
CLINICAL PHARMACOKINETICS (2005)
分享论文
